An important question is whether MAP2K1-driven tumours align with conventional WHO melanomagenesis pathways, alongside BRAF, NRAS, and NF1 mutations, or pathway IV (Spitz), alongside kinase gene fusions and HRAS mutations. The gene discussed is BRAF; the disease is neoplasm.